Influenza Vaccine in HIV Study

University of Melbourne57 enrolled

Overview

The aims of this study are: 1. to investigate if HIV infection alters the antibody responses to influenza and 2. to assess the ability of licensed influenza vaccine to induce functional non-neutralising antibodies in HIV-infected and HIV-uninfected subjects.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Influenza, Human

Interventions

2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)BIOLOGICAL

Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * HIV-1 positive by licensed diagnostic test (for HIV-positive group only) * Planning to receive the seasonal influenza vaccine outside the study * Provision of written informed consent Exclusion Criteria: * Previous allergy to influenza vaccination * Pregnancy or planning to become pregnant * Unwilling or unable to provide blood samples

Outcomes

Primary Outcomes

Anti-influenza antibody responses in plasma with Fc-mediated functions

Time frame: Four weeks after influenza vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.